Varicella Zoster Virus-Specific Immune Responses to a Herpes Zoster Vaccine in Elderly Recipients With Major Depression and the Impact of Antidepressant Medications
Clinical Infectious Diseases2013Vol. 56(8), pp. 1085–1093
Citations Over TimeTop 10% of 2013 papers
Michael R. Irwin, Myron J. Levin, Mark L. Laudenslager, Richard Olmstead, Anne Lucko, Nicholas P. Lang, Carmen Carrillo, Harold A. Stanley, Michael J. Caulfield, Adriana Weinberg, I. S. F. Chan, J. Clair, Jeffrey G. Smith, Rocio D. Marchese, Heather Williams, Dennis Beck, Patricia T. McCook, J. H. Zhang, Gary R. Johnson, Michael N. Oxman
Abstract
Depressed patients have diminished VZV-CMI responses to zoster vaccine, and treatment with antidepressant medication is associated with normalization of these responses. Because higher levels of VZV-CMI correlate with lower risk and severity of HZ, untreated depression may increase the risk and severity of HZ and reduce the efficacy of zoster vaccine.
Related Papers
- → Novel approaches to drug-placebo difference calculation: evidence from short-term antidepressant drug-trials(2011)4 cited
- Drug-placebo difference: in antidepressant drug trials could be 50% greater than previously believed.(2007)
- → Is drug–placebo difference in short-term antidepressant drug trials on unipolar major depression much greater than previously believed?(2008)15 cited
- Research progress on anti-varicella-zoster virus agents(2012)
- → Persistent Pain Following Herpes Zoster (shingles, varicella zoster virus, VZV)(2013)